Secondary acute lymphoblastic leukaemia is constitutional and probably not related to prior therapy
Author:
Affiliation:
1. Memorial Sloan Kettering Cancer Center; New York NY USA
2. Shaare Zedek Medical Centre; Jerusalem Israel
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13386/fullpdf
Reference27 articles.
1. Therapy-related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis;Abdulwahab;Cancer,2012
2. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992;Andersen;British Journal of Haematology,2001
3. Secondary acute lymphoblastic leukemia with t (4;11): report on two cases and review of the literature;Auxenfants;Annals of Hematology,1992
4. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer;Brown;Journal of Clinical Endocrinology and Metabolism,2008
5. Therapy-related acute lymphoblastic leukemia without 11q23 abnormality: report of six cases and a literature review;Chen;American Journal of Clinical Pathology,2010
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pediatric therapy-related hematologic neoplasms show enrichment for KMT2A rearrangement and lymphoblastic phenotype;Leukemia & Lymphoma;2024-08-08
2. Mutational patterns in therapy-related acute lymphoblastic leukemia subgroups: one step closer to unveiling the genetic odyssey;Leukemia & Lymphoma;2024-02-22
3. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry;Bone Marrow Transplantation;2024-01-09
4. ‘Secondary’ acute lymphoblastic/lymphocytic leukemia - done playing second fiddle?;Blood Reviews;2023-07
5. Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal;Blood Advances;2023-06-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3